To identify mechanisms mediating the improved antitumor responses in mice treated with Mito‐ATO, scRNA‐seq analysis was performed on CD45+ tumor infiltrating lymphocytes (TILs) in replicate samples from each treatment (vehicle vs Mito‐ATO) using the LKR13 tumor model. The gene discussed is PTPRC; the disease is neoplasm.